Brimonidine tartrate ophthalmic solution 0.025% for redness relief: an overview of safety and efficacy

Jihei Sara Lee, Chan Yun Kim

Research output: Contribution to journalArticlepeer-review


Introduction: Ocular redness, or conjunctival hyperemia, is a common ophthalmic sign associated with reduced quality of life. For redness without apparent underlying pathology, topical ophthalmic decongestants have been widely used. Areas covered: Brimonidine tartrate was approved in 2017 as a topical vasoconstrictor at a 0.025% concentration for relief of ocular redness. Since then, investigators have reported on efficacy and safety findings from studies evaluating low-dose brimonidine for reducing ocular redness. Expert opinion: Brimonidine is highly selective for α2-adrenergic receptors. Clinical trials have so far shown that the drug in low doses significantly reduces ocular redness in comparison to vehicle for up to 8 hours. Brimonidine-treated eyes did not present side effects of other vasoconstrictors, such as hypotension, cardiac arrhythmia, or drowsiness. Ocular adverse events, such as allergic reactions and redness rebound, were also minimal. In this review, we examine in detail published literature on the mechanism of brimonidine tartrate and its efficacy and safety in relieving conjunctival hyperemia.

Original languageEnglish
Pages (from-to)911-919
Number of pages9
JournalExpert Review of Clinical Pharmacology
Issue number8
Publication statusPublished - 2022

Bibliographical note

Funding Information:
This paper was funded by the Basic Science Research Program through the National Research Foundation of Korea (No. NRF-2019 R1A2C1091089). The funding organization had no role in the design or conducting of this research.

Publisher Copyright:
© 2022 Informa UK Limited, trading as Taylor & Francis Group.

All Science Journal Classification (ASJC) codes

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)


Dive into the research topics of 'Brimonidine tartrate ophthalmic solution 0.025% for redness relief: an overview of safety and efficacy'. Together they form a unique fingerprint.

Cite this